Paving ways for personalizing drug therapy during pregnancy:A focus on the risk of drug teratogenicity by Daud, Nur
  
 University of Groningen
Paving ways for personalizing drug therapy during pregnancy
Daud, Nur
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Daud, N. (2017). Paving ways for personalizing drug therapy during pregnancy: A focus on the risk of drug
teratogenicity. [Groningen]: Rijksuniversiteit Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
3chapter
Daud ANA, Bergman JEH, Oktora MP, Kerstjens-Frederikse WS, Groen H, 
Bos HJ, Hak E, Wilffert B
PLOS ONE 2017; 12(3): e0173530; https://doi.org/10.1371/journal.pone.0173530
Maternal use of drug substrates of placental 
transporters and the effect of transporter-




























































Background: A number of  transporter proteins are expressed in the placenta, and 
they facilitate the placental transfer of  drugs. The inhibition of  P-glycoprotein (P-
gp) was previously found to be associated with an increase in the risk of  congenital 
anomalies caused by drug substrates of  this transporter. We now explore the role of  
other placental transporter proteins.
Methods: A population-based case-referent study was performed using cases with 
congenital anomalies (N=5,131) from EUROCAT Northern Netherlands, a registry 
of  congenital anomalies. The referent population (N=31,055) was selected from the 
pregnancy IADB.nl, a pharmacy prescription database. 
Results: Ten placental transporters known to have comparable expression levels 
in the placenta to that of  P-gp, were selected in this study. In total, 147 drugs were 
identified to be substrates, inhibitors or inducers, of  these transporters. Fifty-eight 
of  these drugs were used by at least one mother in our cases or referent population, 
and 28 were used in both. The highest user rate was observed for the substrates of  
multidrug resistance-associated protein 1, mainly folic acid (6% of  cases, 8% of  
referents), and breast cancer resistance protein, mainly nitrofurantoin (2.3% of  cases, 
2.9% of  referents). In contrast to P-gp, drug interactions involving substrates of  these 
transporters did not have a significant effect on the risk of  congenital anomalies.
Conclusions: Some of  the drugs which are substrates or inhibitors of  placental 
transporters were commonly used during pregnancy. No significant effect of  
transporter inhibition was found on fetal drug exposure, possibly due to a limited 


























































Drug use in pregnancy raises many concerns about the risk of  harmful effects on 
the fetus while the use of  these medications is inevitable to control certain medical 
conditions. The potential harmful effects of  drugs on the fetus are dependent upon, 
among others, the concentration of  drug that reaches the fetal circulation, a factor 
which is partly modulated by placental transport of  drugs. 
A number of  transporter proteins are expressed in the placenta to facilitate the 
transport of  biological substances to and from the fetus, including a subset of  drugs 
(1-4). This transport can be modulated by interactions with other drugs transported 
by the same transporter. These interactions may result in changes in substrate 
concentration in the fetal circulation without affecting the maternal blood or plasma 
concentration of  substrate drugs (5). The effect of  drug interactions mediated by 
P-glycoprotein (P-gp), the most studied transporter protein, on fetal drug exposure 
has been described earlier (6-11). From our previous study, the risk of  specific 
fetal congenital anomalies was increased when the mothers used P-gp substrates in 
combination with other substrates or inhibitors (11). 
To date, the effects of  drug interactions mediated by other placental transporters 
were observed only in in vitro studies (5,12,13). Therefore, we aimed to describe the 
user rates of  drugs transported by placental transporters during the first trimester of  
pregnancy using population-based databases. The second objective was to investigate 
the effect of  drug interactions mediated by these transporters on fetal drug exposure 
by assessing the changes in the risk of  congenital anomalies. 
METHODS  
Cases sampling
Cases were selected from EUROCAT Northern Netherlands (NNL), a population-
based registry for children with congenital anomalies born in the Northern 
provinces of  the Netherlands. EUROCAT NNL registers fetuses or children with 
major congenital anomalies diagnosed before or after birth, and up to 10 years old, 
upon consent for their parents. The information available in the database includes 
sociodemographic characteristics of  the parents and lifestyle during pregnancy. The 
information on drug intake was obtained from pharmacy records and then verified 
by a telephone interview with the mothers. Drug use was coded using the Anatomical 



























































Cases of  major and minor congenital anomalies were classified according to 
EUROCAT Subgroup of  Congenital Anomalies version 2012 (14), the International 
Classification of  Diseases (ICD) coding system 9th revision for cases registered until 
2001, and ICD 10th revision for cases registered from 2002 onwards. We included 
only major anomalies: anomalies of  the nervous system, eye, ear, face & neck, heart, 
respiratory, oro-facial clefts, digestive system, urinary, genital, and limb (Appendix 
2.1). 
There are 6,059 cases, excluding cases with chromosomal anomalies, born between 
January 1, 1997 and December 31, 2013 and registered in EUROCAT NNL in 
March 2015. This number includes only those children whose mothers had a history 
of  medication use at any time during pregnancy in order to match with the referent 
population of  drug users from the prescription database. We excluded 572 cases with 
genetic disorders, i.e. microdeletion and monogenic disorders. To avoid selection bias 
in drug prescribing, we included only the first malformed child or pregnancy, which 
resulted in 5,131 cases. 
Referent population sampling
The referent population was selected from IADB.nl, a population-based prescription 
database in the Netherlands. IADB.nl holds the pharmacy data from about 600,000 
people, covering several parts of  the country, mostly in the Northern provinces. The 
data were collected from 60 participating community pharmacies, and the prescription 
rates of  the IADB.nl population were found to be representative for the population 
in the Netherlands as a whole (15). Prescriptions registered in the database were 
prescribed by general practitioners or specialists, which include the name of  the drugs, 
the dispensing date, the ATC codes, dose and quantity dispensed (15).
For studies on drug use in pregnancy, Pregnancy IADB.nl was constructed based on 
the main IADB.nl, with linkage of  prescription data of  mother and child based on 
the coding of  home address. The date of  conception was determined by assuming a 
gestational age 273 days before the date of  birth of  the linked child. Twin or triplet 
pregnancies were excluded because the gestation period is likely to be shorter than 
singleton pregnancies. Details of  the linkage and their validation are as reported 
earlier (16). We selected children born within the same time period as the cases, 
whose mothers were registered with complete information on drug use. We then 
selected only the first registered pregnancy (N=31,311) to avoid selection bias in the 
drugs prescribed, since the drug selection may be influenced by the outcome of  a 
previous pregnancy. Since EUROCAT NNL and Pregnancy IADB.nl cover a similar 

























































We therefore excluded 256 children (0.8% out of  31,311) from the Pregnancy IADB.
nl, because the birth dates of  the mothers and children, and the gender of  the child 
matched with the children in EUROCAT NNL. 
Drug exposure definitions  
Selection of  placental transporters proteins and drug substrates
Our previous study showed that P-gp inhibition was associated with an increased risk 
of  congenital anomalies caused by drug substrates of  P-gp, suggesting the importance 
of  this transporter in fetal drug exposure (11). Therefore, in this study, we included 
all other placental transporters that have mRNA expression level in the placenta at 
least comparable to that of  P-gp, which is 0.0255 as a ratio of  the expression of  
peptidylprolyl isomerase (PPIA) mRNA, a housekeeping gene (17-19). From these 
transporters, protein expression of  breast cancer resistance protein (BCRP), organic 
cation transporter 3 (OCT3), organic anion transporter 4 (OAT4) and organic anion 
transporting polypeptide 2B1 (OATP2B1) was detected in the first trimester placenta 
so far (20-22). The expression of  BCRP increases throughout gestation but later 
decreases within the third trimester, while OCT3 is moderately increased throughout 
gestation (21,23,24).  As for OAT4 and OATP2B1, not much has been reported on 
the changes of  placental expression of  these transporters during pregnancy. For the 
other transporters no protein expression data are available.
The selection of  drug substrates of  the transporters is based on review articles that 
report the results from in vitro and in vivo studies (5,25-29). The articles were searched 
in PubMed using combinations of  these keywords: "placenta", "drug transporters", 
"drug substrate", "drug inhibitor", "Breast Cancer Resistance Protein", "ABCG2", 
"Multidrug resistance-associated proteins", "MRP1", "Organic anion transporters", 
"OAT4", "OATP2B1", "OCT3", "Monocarboxylate transporters”, "MCT1", "MCT4", 
"MCT8", "MCT10", "equilibrative nucleoside transporters", and "ENT1". These 
drugs were classified according to substrate affinity to each placental transporter, 
including substrate, substrate/inhibitor, inhibitor, substrate/inducer and inducer, as 


























































User rates of  drugs associated with placental transporters 
For the first objective, we described the user rates of  drugs associated with transporter 
proteins between cases and referent population. User rates were defined as the self-
reported use of  (in cases), or the pharmacy dispensing of  (in referent population) the 
selected drugs, from three months before the estimated conception date through the 
first three months of  pregnancy. We included the preconception period because the 
drugs may be continually used during the first trimester of  pregnancy, for the referent 
population. The use of  OTC drugs was disregarded because the Pregnancy IADB.
nl does not register the use of  these drugs. However, prescribing regulations for 
ranitidine, ibuprofen and aspirin changed in the Netherlands during the study period, 
as reported by the Medicines Evaluation Board of  the Netherlands. Therefore, we 
only included the use of  prescribed ranitidine, ibuprofen and aspirin among cases. 
Since folic acid is usually taken as an OTC medication, its use was also included only 
when it was prescribed.
Drug interactions and the risk of  congenital anomalies
For the second objective, we explored the effect of  drug-drug interactions involving 
placental transporter proteins on the risk of  fetal teratogenicity. We assessed the 
risk of  overall congenital anomalies with the use of  all substrates of  each placental 
transporter. The analyses were performed for individual transporters, as fetal drug 
exposure may depend upon whether the influx or efflux has changed, and the 
localization of  the transporters. Since BCRP is known to be involved in a vectorial 
transport with OATP2B1 (1), we also determined the effect of  drug interactions 
involving the substrates of  both placental transporters. 
Statistical analysis
The user rates of  the selected drugs were calculated by using the total number of  
cases or the population as the denominator. For the drug interaction study, binary 
logistic regression was used to calculate odds ratios (OR) and 95% confidence 
intervals for the risk of  anomalies with each drug interaction pattern. Analyses were 


























































Selection of  placental transporters and drug substrates
Our study focused on placental transporters that have comparable expression levels 
to P-gp in the placenta, and we have identified ten eligible placental transporters: 
BCRP and multidrug resistance-associated protein 1 (MRP1) as efflux transporters, 
while OCT3, equilibrative nucleoside transporter (ENT1), OAT4, OATP2B1 and 
monocarboxylate transporters 1, 4, 8 and 10 (MCT1, MCT4, MCT8, MCT10) as 
influx transporters. The localization of  these transporters in placental tissue and the 
direction of  substrate transport are as depicted in Figure 1.
From the literature, 168 drugs are classified to be associated with the transport of  
these placental transporters, either as substrates, inducers or inhibitors. We excluded 
21 of  these drugs because they are either experimental or veterinary drugs, or without 
ATC codes. There were a total of  147 drugs selected to investigate the first objective: 
53 drugs associated with BCRP transport, 45 drugs with OCT3, 29 drugs with OAT4, 
28 drugs with MRP1, 24 drugs with OATP2B1, 8 drugs with ENT1, 10 drugs with 
MCT1, 6 drugs with MCT4, and 3 drugs with both MTC8 and MCT10 (one drug 
may be associated with the transport of  more than one transporter). The list of  all 
placental transporters included in this study and their respective drug substrates, 


























































Figure 1: Placental transporter proteins are expressed on either side of  the placenta. 
Five transporter proteins are expressed in the apical (maternal-facing) layer of  
placental cells, which include breast cancer resistance protein (BCRP),  equilibrative 
nucleoside transporter (ENT), monocarboxylate transporter 4, 8, 10 (MCT4, 
MCT8, MCT10). Another five are expressed in the basolateral (fetal-facing) layer 
of  placental cells, including multidrug resistance-associated protein (MRP), organic 
cation transporter 3 (OCT3), organic anion transporter 4 (OAT4),  organic anion 
transporting polypeptide 2B1 (OATP2B1) and monocarboxylate transporter 1 

























































User rates of  drugs associated with placental transporters among cases and the referent population 
Characteristics of  children born to case mothers and to mothers in the referent 
population are shown in Table 1. The mothers in the case group were slightly older 
than the mothers in the referent population (30.2 ± 4.6 years and 29.5 ± 4.9 years, 
respectively, p< 0.01). The majority of  cases were liveborn while all the children in the 
referent population were live born. The most common types of  anomalies among the 
case group were heart and limb anomalies (around 25% each), followed by anomalies 
in the digestive system (12.3%). 
Out of  147 drugs associated with placental transporters, 58 were used by at least 
one mother in either the cases or the referent population, as listed in Table 2. Only 
28 of  the drugs were used by at least one mother in both groups. Table 3 shows the 
percentage of  mothers who used at least one of  the drugs, according to their substrate 
specificity to each placental transporter protein. We found no users of  drugs that 
are substrates/inducers or inducers of  these transporters. The use of  MRP1 drug 
substrates was most common as compared to substrates of  other transporters; it was 
observed in 6% of  the case mothers and 8% of  the referent population. The highest 
user rate was for folic acid (prescribed), as one of  the substrates of  MRP1. BCRP 
substrates were used in 3% and 3.6% of  the case and referent population, respectively. 
The percentage resulted largely from the use of  nitrofurantoin (2.3% and 2.9% in 
cases and referent population, respectively). Restricting the analysis for liveborn cases 
only showed a slight reduction in user rates for each transporter (Table 2 and 3).
Placental transporter-mediated drug interactions and the risk of  congenital anomalies
Drug interaction analysis can only be done for MRP1, BCRP and MCT1 substrates.  
There were no users of  OCT3, OAT4, OATP2B1 and MCT4 substrates in 
combination with an inhibitor to calculate the OR. Due to limited sample size, we 
were not able to show any significant increase in the risk of  congenital anomalies with 


























































Table 1: Characteristics of  children born to case mothers and referent population 
mothers
Characteristics Cases (N=5,131) Referent population 
(N=31,055)
Maternal age at delivery*, mean years 
+ s.d
30.2 + 4.6 29.5 + 4.9
Gender, N (%)
   Boy 2,864 (55.8) 16,064 (51.7)
   Girl 2,259 (44.0) 14,991 (48.3)
   Missing data 8 (0.2) -
Year of  birth, N (%)
   1997-1998 665 (13.0) 5,736 (18.5)
   1999-2000 695 (13.5) 5,492 (17.7)
   2001-2002 634 (12.4) 4,551 (14.7)
   2003-2004 620 (12.1) 3,954 (12.7)
   2005-2006 637 (12.4) 3,247 (10.5)
   2007-2008 576 (11.2) 2,927 (9.4)
   2009-2010 658 (12.8) 2,805 (9.0)
   2011-2012 527 (10.3) 1,983 (6.4)
   2013 119 (2.3) 360 (1.2)
Type of  birth, N (%)
   Live birth 4,805 (93.6) 31,055 (100.0)
   Termination of  pregnancy 224 (4.4) 0
   Stillbirth 65 (1.3) 0
   Miscarriage (>24 weeks) 37 (0.7) 0
Types of  anomaliesa, N (%)
   Heart 1,377 (26.8) - 
   Limb 1,228 (23.9) -
   Digestive 633 (12.3) -
   Urinary 563 (11.0) -
   Clefts 457 (8.9) -
   Genital 444 (8.7) -
   Central nervous system 383 (7.5) -
   Eye, ear, face and neck 175 (3.4) -
   Respiratory 91 (1.8) -
*p-value < 0.01; s.d, standard deviation; a cases with multiple congenital anomalies are represented in 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Placental transporters may potentially play a role in fetal drug transfer in view of  the 
vast range of  drugs transported by these transporters. For ten placental transporters 
included in this study, 28 drugs were reported in in-vitro or ex-vivo studies to be 
substrates or inhibitors, and these were used by at least one pregnant woman in both 
the case group and the referent population. For each placental transporter, the number 
of  mothers who used drug substrates were generally lower than for P-gp, (the use of  
P-gp drug substrates was 10% in cases and 12% in the referent population) (11). This 
is probably because the substrates for those transporters are much less studied and 
therefore much less is known about them as compared to P-gp substrates. 
Knowledge about the expression of  most of  the placental transporters in this study 
is relatively new, and their contribution to drug transport in the placenta has not 
been completely characterized. Despite that, transporter-mediated drug interactions 
can potentially cause clinically relevant changes in drug pharmacokinetics and drug 
exposure, as previously observed for P-gp, BCRP and MRPs (5,30).  In this study, we 
did not find significant changes in the risk for congenital anomalies by inhibitors of  
the placental transporters studied, possibly due to the limited number of  users in each 
drug interaction pattern.
There are also several other factors that should be taken into consideration in 
interpreting the role of  placental transporters in the fetal drug exposure. First, the 
same efflux and influx transporters are also present in other tissues (i.e. intestine and 
liver), which are important for the distribution and elimination of  their substrates. 
Drug interactions in these tissues, apart from the placenta, may affect substrate 
exposure to the fetus. However, these interactions did not warrant pharmacovigilance 
measures so far, therefore we do not expect these interactions to have a significant 
impact on our results. Second, there is high inter-individual variation in the 
expression of  these transporters due to genetic variability in the genes encoding 
for them (4,12). Genotype-dependent transporter-mediated drug interactions have 
not yet been well studied, but the effect was already observed for fexofenadine and 
OATP2B1 inhibition (31), and for metformin and OCT2 inhibition (32). Third, drug 
pharmacokinetics in the maternal circulation are also altered during pregnancy due to 
normal physiological changes (33,34), and possible drug-drug interaction involving 
metabolic enzymes, i.e. CYP450. However, using the software-supported medications 
surveillance system in the Netherlands, these interactions may have been avoided 
during the prescribing and dispensing process. Therefore, we assumed that, at least 
from 2002, the clinically significant CYP-mediated drug interactions had already 


























































substrate specificities, and the net effect of  drug interactions involving substrates with 
more than one transporter is difficult to measure. 
Our study has several strengths and limitations. One of  the strengths is that the 
information on drug use was well documented in both databases. Duration of  drug 
use is well documented with minimal recall bias, and the inclusion of  mother-children 
pair was done over the same period of  years. Further, our study is among the first 
to investigate the role of  transporter proteins in the placenta using a population-
based study. Our knowledge of  fetal transfer of  drugs was previously based on 
in vitro studies using cell lines and ex vivo placental models, which do not take into 
consideration the other clinical parameters involved (36,37). Moreover, limited 
methods can be used to study the role of  transporters in the early stage of  pregnancy, 
which is a crucial period for fetal development.
One limitation of  our study is the potential for misclassification of  drug exposure in 
the prescription database (Pregnancy IADB.nl) because we cannot be sure that the 
mothers actually took the drugs dispensed. Further, the period of  exposure was an 
estimation calculated from the date of  delivery with the assumption of  273 days of  
gestation. If  the mothers were classified as exposed when they were not, it would 
lead to an underestimation of  the observed risk. Another limitation is that placental 
transporter expression, instead of  protein level, is used and the assumption of  drug 
interactions at the placenta is based on drugs prescribed and not on measured drug 
concentrations. Confounding by indication is also impossible to address because 
nothing is known in our databases about the medical condition for which the drug 
was prescribed and used. Finally, as acknowledged earlier, despite a large number of  
cases and referents, due to a wide variety of  exposures, we had limited power to detect 
statistically significant effects.
In conclusion, we classified drugs based on their substrate specificity to several 
placental transporter proteins, and described the use of  these drugs during the first 
trimester of  pregnancy. Using the same approach as in our previous study on P-gp, 
we were unable to find a significant association between the inhibition of  these 
transporters and the risk of  congenital anomalies. We did not have enough power 
to draw conclusions on the causality, and larger databases are needed to answer this 
question. However, the list of  substrates for each transporter may not be complete, 
and therefore the effect of  drug interactions may be underestimated. Nonetheless, 
knowledge about transporter-mediated drug interactions in the placenta is clearly 
important for drugs with known risk of  teratogenicity. Larger-scale databases are 
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